Stock price fluctuations and occasional sharp drops for clinical-stage biotechnology companies like Keros Therapeutics are frequently driven by investor reactions to clinical trial data announcements, regulatory updates, or broader macroeconomic trends affecting the growth and healthcare sectors. Whenever interim or top-line clinical data from pipeline candidates do not completely meet aggressive investor expectations, or when broader market sentiment shifts away from risk-on speculative equities toward safer assets, shares can experience downward pressure. Additionally, capital-raising activities, such as secondary stock offerings or convertible debt issuances to fund ongoing research, can temporarily impact near-term equity valuations.